High-Dose, Long-Term, Continuous Subcutaneous Infusion of SMS 201–995 (Sandostatin®) in Acromegaly

  • S. Chatterjee
  • M. C. White
  • N. Møller
  • K. Hall
  • M. J. Dunne
  • E. R. Baister
  • P. Kendall-Taylor
Conference paper

Abstract

Acute and chronic studies have demonstrated the effectiveness of the long-acting somatostatin analogue SMS 201–995 (Sandostatin®) in the treatment of acromegaly. Daily doses of 100–300 µg Sandostatin given as multiple injections in most cases induce satisfactory suppression of GH release. No consistent shrinkage of the pituitary tumour has been demonstrated.

Keywords

Toxicity Dopamine Shrinkage Statin Cose 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Copyright information

© Springer-Verlag, Berlin Heidelberg 1988

Authors and Affiliations

  • S. Chatterjee
    • 1
    • 2
  • M. C. White
    • 1
    • 2
  • N. Møller
    • 1
    • 2
  • K. Hall
    • 1
    • 2
  • M. J. Dunne
    • 1
    • 2
  • E. R. Baister
    • 1
    • 2
  • P. Kendall-Taylor
    • 1
    • 2
  1. 1.Departments of Medicine and RadiologyUniversity of Newcastle upon TyneUK
  2. 2.Sandoz Laboratories LtdBasleSwitzerland

Personalised recommendations